Alerts will be sent to your verified email
Verify Email
BAFNAPH
|
Bafna Pharma
|
Krebs Biochem.&Inds
|
Aarey Drugs & Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-52.11 % | 56.46 % | 5.07 % |
|
5yr average Equity Multiplier
|
3.77 | -2.97 | 2.28 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 0.3 | 1.56 |
|
5yr Avg Net Profit Margin
|
-36.55 % | -60.0 % | 1.44 % |
|
Price to Book
|
3.99 | 0.0 | 1.41 |
|
P/E
|
49.07 | 0.0 | 48.58 |
|
5yr Avg Cash Conversion Cycle
|
0.18 Days | -861.42 Days | 77.34 Days |
|
Inventory Days
|
87.65 Days | 115.42 Days | 20.31 Days |
|
Days Receivable
|
132.64 Days | 8.79 Days | 172.65 Days |
|
Days Payable
|
210.48 Days | 408.94 Days | 98.9 Days |
|
5yr Average Interest Coverage Ratio
|
-5.68 | -5.02 | 4.14 |
|
5yr Avg ROCE
|
-11.61 % | -22.06 % | 8.93 % |
|
5yr Avg Operating Profit Margin
|
-21.98 % | -38.55 % | 1.54 % |
|
5 yr average Debt to Equity
|
1.41 | -2.12 | 0.21 |
|
5yr CAGR Net Profit
|
12.0 % | -7.31 % | -4.17 % |
|
5yr Average Return on Assets
|
-16.11 % | -17.59 % | 2.26 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 72.74 % | 44.8 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-15.42 % | 0.0 | -3.26 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bafna Pharma
|
Krebs Biochem.&Inds
|
Aarey Drugs & Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|